Prescribe pregabalin by brand for pain, GPs told

Pregabalin should only be prescribed for the treatment of neuropathic pain under the brand name Lyrica, NHS England has advised.

Lyrica is the only pregabalin product currently licensed for the treatment of neuropathic pain. | SCIENCE PHOTO LIBRARY
Lyrica is the only pregabalin product currently licensed for the treatment of neuropathic pain. | SCIENCE PHOTO LIBRARY

When prescribing pregabalin for the treatment of neuropathic pain, prescribers should write the prescription with the brand name 'Lyrica', and not the generic name or the name of any other brand.

In the event of clinical contraindications or other considerations relating specifically to Lyrica (such as allergy to an excipient or unavailability of the branded product), neither Lyrica nor pregabalin should be prescribed.

Pregabalin should continue to be prescribed generically for all other indications.

This advice has been issued following the introduction of new pregabalin products, including Lecaent and Rewisca, with the expiry of patent protection for Lyrica in the treatment of epilepsy and generalised anxiety disorder. The patent remains in force for use of the product in neuropathic pain.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more